Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.